TY - JOUR
T1 - Correction: Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
AU - Hua, Yichao
AU - Vella, Gerlanda
AU - Rambow, Florian
AU - Allen, Elizabeth
AU - Martinez, Asier Antoranz
AU - Duhamel, Marie
AU - Takeda, Akira
AU - Jalkanen, Sirpa
AU - Junius, Steffie
AU - Smeets, Ann
AU - Nittner, David
AU - Dimmeler, Stefanie
AU - Hehlgans, Thomas
AU - Liston, Adrian
AU - Bosisio, Francesca Maria
AU - Floris, Giuseppe
AU - Laoui, Damya
AU - Hollmén, Maija
AU - Lambrechts, Diether
AU - Merchiers, Pascal
AU - Marine, Jean-Christophe
AU - Schlenner, Susan
AU - Bergers, Gabriele
N1 - Publisher Copyright:
© 2022 The Author(s)
Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.
PY - 2023/1/9
Y1 - 2023/1/9
N2 - (Cancer Cell 40, 1600–1618; December 12, 2022) In this article, the authors demonstrated that antiangiogenic immunotherapies differentiate postcapillary venules into high-endothelial venules (HEVs) that foster permissive TCF1
+ T lymphocyte niches. In the introduction, they mistakenly stated that HEVs express L-Selectin/CD62L, while HEVs express the sulphated and glycosylated ligands for L-Selectin/CD62L. The original article has been corrected online. The authors regret this error and apologize for any confusion this might have caused.
AB - (Cancer Cell 40, 1600–1618; December 12, 2022) In this article, the authors demonstrated that antiangiogenic immunotherapies differentiate postcapillary venules into high-endothelial venules (HEVs) that foster permissive TCF1
+ T lymphocyte niches. In the introduction, they mistakenly stated that HEVs express L-Selectin/CD62L, while HEVs express the sulphated and glycosylated ligands for L-Selectin/CD62L. The original article has been corrected online. The authors regret this error and apologize for any confusion this might have caused.
UR - http://www.scopus.com/inward/record.url?scp=85144352117&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2022.12.006
DO - 10.1016/j.ccell.2022.12.006
M3 - Article
C2 - 36626867
VL - 41
SP - 226
EP - 226
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 1
ER -